J&J's Apalutamide, Astellas/Pfizer's Xtandi On Par For Non-Metastatic Prostate Cancer

 
• By Emily Hayes

Phase III data at ASCO GU meeting impress, but raise questions about safety in new non-metastatic CRPC indication – rash, fractures and falls for Erleada (apalutamide) and unexplained deaths after termination of treatment for Xtandi (enzalutamide).

golden gift boxes isolated on white background

More from Anticancer

More from Therapy Areas